2015 International Symposium on Malignant Mesothelioma
The conference is geared to attendees from all walks of life, including patients and their families, advocates, medical professionals, those who have lost loved ones to mesothelioma, and scientists.
Alexandria, VA (PRWEB) December 30, 2014
Last week, supporters of the Mesothelioma Applied Research Foundation received in the mail a brochure about the 2015 International Symposium on Malignant Mesothelioma, which listed activities and speakers.
Currently scheduled to speak are:
- H. Richard Alexander, MD, Chair, Science Advisory Board, Meso Foundation, University of Maryland School of Medicine
- Samuel G. Armato, III, PhD, University of Chicago
- Francine Baumann, PhD, University of Hawaii
- Maja Belamaric, Director of Communications, Meso Foundation
- Ann Berger, MSN, MD, National Institutes of Health
- Diane M. Blackburn
- Alain Borczuk, MD, Columbia University
- Julie Brahmer, MD, Johns Hopkins
- Raphael Bueno, MD, Brigham and Womens Hospital
- M. Catherine Bushnell, PhD, National Institutes of Health
- Melpo Christofidou-Solomidou, PhD, University of Pennsylvania
- Robert A. Cosentino
- Melissa Culligan, NP, University of Maryland
- Liz Darlison, Mesothelioma UK
- Cam Deaver
- Dean Fennell, PhD, University of Leicester
- Joseph Friedberg, MD, University of Maryland
- Mike G. Hackler, The Olivier Group, LLC
- Raffit Hassan, MD, National Institutes of Health
- Mary Hesdorffer, MS, APRN, Executive Director, Meso Foundation
- Judith Hicks
- Melinda Kotzian, Chief Executive Officer, Meso Foundation
- Lee M. Krug, MD, Chair, Board of Directors, Meso Foundation,
Memorial Sloan Kettering Cancer Center
- Deborah S. Levinson
- Eric R. Linthicum
- Brian W. Loggie, MD, Creighton University Medical Center
- Carol Michaels
- Julian Molina, MD, PhD, Mayo Clinic
- Lora Mosca
- Linda Nebeling, PhD, National Institutes of Health
- Prof. Anna Nowak, University of Western Australia
- Harvey Pass, MD, NYU Langone Medical Center
- Olga Pavlick
- Miriam Ratner
- Sandy Robb
- Erica Ruble, Development Assistant, Meso Foundation
- Gary Shelton, MSN, NP; ANP-BC, AOCNP, NYU Clinical Cancer Center
- Daniel Sterman, MD, New York University School of Medicine
- Robert N. Taub, MD, Columbia University
- Dennis A. Wigle, MD, PhD, Mayo Clinic
- Marjorie Zauderer, MD, Memorial Sloan Kettering Cancer Center
Daytime conference sessions will take place on the campus of the National Institutes of Health in Bethesda, while dinners, including a community dinner and an awards ceremony, will be held at the Hyatt Regency Bethesda.
Sessions will cover a range of topics about pleural and peritoneal mesothelioma, treatments, clinical trials, surgery, prevention, as well as support groups, well-being, and community sessions. Additionally, a mesothelioma Advocacy Day will be held on Wednesday, March 4th.
The conference is geared to attendees from all walks of life, including patients and their families, advocates, medical professionals, those who have lost loved ones to mesothelioma, and scientists. The Symposium provides a unique setting for everyone in the mesothelioma community to come together, learn about mesothelioma and its treatments for renowned experts, build friendships and socialize.
In addition to science and treatment sessions for the general public, this year’s Symposium includes a two-day special session for scientists and medical professionals. Nearly 100 mesothelioma experts will come together to share their work, and find collaboration opportunities, in an effort to speed up mesothelioma advances. These sessions feature a separate list of speakers.
Registration for the Symposium is now open at curemeso.org/symposium, where attendees can also book their hotel rooms. A general schedule and further information about the conference can also be found on this page.
Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. With the life expectancy of less than one year after diagnosis, medical experts consider it one of the most aggressive and deadly of all cancers. An estimated one-third of those who develop mesothelioma were exposed while serving in the Navy or working in shipyards. Currently, few treatment options exist. There is no cure.
ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)(3) nonprofit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer-reviewed scientific research to develop life-saving treatments for this extremely aggressive cancer. To date, the Foundation has awarded over $9 million to research. More information is available at http://www.curemeso.org.